Predictive factor for the response to adjuvant therapy with emphasis in breast cancer
AUTOR(ES)
Munster, Pamela N
FONTE
BioMed Central
RESUMO
One of the major challenges of early-stage breast cancer is to select the adjuvant therapy that ensures the most benefits and the least harm for the patient. The definition of accurate predictive factors is therefore of paramount importance. So far the choice of adjuvant therapy has been based on the number of affected lymph nodes and the hormone receptor status of the patient. This paper evaluates the use of other tumor-related markers as predictive factors for adjuvant therapy. These include HER2, p53 and Bcl-2, cathepsin B, p27, proliferating cell nuclear antigen (PCNA), cyclin D, Ki-67, and vascular endothelial growth factor (VEGF).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=138701Documentos Relacionados
- Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer
- Akt kinases in breast cancer and the results of adjuvant therapy
- Adjuvant Hormonal Therapy Use Among Insured, Low-Income Women With Breast Cancer
- Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-negative breast cancer (summary of the 2001 update)
- Clinical practice guidelines for the care and treatment of breast cancer: adjuvant systemic therapy for node-positive breast cancer (summary of the 2001 update)
